Check out my latest monthly review! It showcases Blue Steens’ latest posts, some news from biopharma & medtech as well as interesting events I have attended or noticed. At a glance We’ve seen more reliable COVID-19 serological tests coming out on the market as well as clinical trials commencing and early results being released. Quite a few virtual events have […]
Check out my latest monthly review! It summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those in need. The complex journey for a pharmaceutical to gain patient access continues.
Check out my latest monthly review! It summarises Blue Steens’ latest posts and showcases some informative online content that I haven’t released elsewhere. Click to read >>>
I feel that there is considerable confusion about drug prices amongst industry outsiders. Until I started looking into the topic, I had no idea how complex it was.
In 2019, I graduated with Distinction from the roller-coaster that was my one-year full-time MSc in Finance and Investment Management at the University of Aberdeen, Scotland.
Considering the importance of antibiotics for our healthcare, the issue of a dwindling development pipeline must be addressed. This article outlines various economic suggestions.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.